Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9)

Takeshi Suto; Megumi Ishiguro; Chikuma Hamada; Katsuyuki Kunieda; Hiroyuki Masuko; Ken Kondo; Hideyuki Ishida; Genichi Nishimura; Kazuaki Sasaki; Takayuki Morita; Shoichi Hazama; Koutarou Maeda; Hideyuki Mishima; Hideyuki Ike; Sotaro Sadahiro; Kenichi Sugihara; Masazumi Okajima; Shigetoyo Saji; Junichi Sakamoto; Naohiro Tomita

doi:10.1007/s10147-017-1146-6

Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9)

Takeshi Suto, Megumi Ishiguro, Chikuma Hamada, Katsuyuki Kunieda, Hiroyuki Masuko, Ken Kondo, Hideyuki Ishida, Genichi Nishimura, Kazuaki Sasaki, Takayuki Morita, Shoichi Hazama, Koutarou Maeda, Hideyuki Mishima, Hideyuki Ike, Sotaro Sadahiro, Kenichi Sugihara, Masazumi Okajima, Shigetoyo Saji, Junichi Sakamoto, Naohiro Tomita

International Medical Center

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the original publication of the article, Fig. 1 was published with incorrect numbers of patients (n). The correct Fig. 1 is given in this erratum.

Original language	English
Pages (from-to)	805-806
Number of pages	2
Journal	International Journal of Clinical Oncology
Volume	22
Issue number	4
DOIs	https://doi.org/10.1007/s10147-017-1146-6
Publication status	Published - 01-08-2017

All Science Journal Classification (ASJC) codes

Surgery
Hematology
Oncology

Access to Document

10.1007/s10147-017-1146-6

Fingerprint

Dive into the research topics of 'Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9)'. Together they form a unique fingerprint.

Cite this

Suto, T., Ishiguro, M., Hamada, C., Kunieda, K., Masuko, H., Kondo, K., Ishida, H., Nishimura, G., Sasaki, K., Morita, T., Hazama, S., Maeda, K., Mishima, H., Ike, H., Sadahiro, S., Sugihara, K., Okajima, M., Saji, S., Sakamoto, J., & Tomita, N. (2017). Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9). International Journal of Clinical Oncology, 22(4), 805-806. https://doi.org/10.1007/s10147-017-1146-6

Suto, Takeshi ; Ishiguro, Megumi ; Hamada, Chikuma ; Kunieda, Katsuyuki ; Masuko, Hiroyuki ; Kondo, Ken ; Ishida, Hideyuki ; Nishimura, Genichi ; Sasaki, Kazuaki ; Morita, Takayuki ; Hazama, Shoichi ; Maeda, Koutarou ; Mishima, Hideyuki ; Ike, Hideyuki ; Sadahiro, Sotaro ; Sugihara, Kenichi ; Okajima, Masazumi ; Saji, Shigetoyo ; Sakamoto, Junichi ; Tomita, Naohiro. / Erratum to : Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9). In: International Journal of Clinical Oncology. 2017 ; Vol. 22, No. 4. pp. 805-806.

@article{dfb72d7a7402488386b6acae834f1d71,

title = "Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9)",

abstract = "In the original publication of the article, Fig. 1 was published with incorrect numbers of patients (n). The correct Fig. 1 is given in this erratum.",

author = "Takeshi Suto and Megumi Ishiguro and Chikuma Hamada and Katsuyuki Kunieda and Hiroyuki Masuko and Ken Kondo and Hideyuki Ishida and Genichi Nishimura and Kazuaki Sasaki and Takayuki Morita and Shoichi Hazama and Koutarou Maeda and Hideyuki Mishima and Hideyuki Ike and Sotaro Sadahiro and Kenichi Sugihara and Masazumi Okajima and Shigetoyo Saji and Junichi Sakamoto and Naohiro Tomita",

note = "Publisher Copyright: {\textcopyright} 2017, Japan Society of Clinical Oncology.",

year = "2017",

month = aug,

day = "1",

doi = "10.1007/s10147-017-1146-6",

language = "English",

volume = "22",

pages = "805--806",

journal = "International Journal of Clinical Oncology",

issn = "1341-9625",

publisher = "Springer Japan",

number = "4",

}

Suto, T, Ishiguro, M, Hamada, C, Kunieda, K, Masuko, H, Kondo, K, Ishida, H, Nishimura, G, Sasaki, K, Morita, T, Hazama, S, Maeda, K, Mishima, H, Ike, H, Sadahiro, S, Sugihara, K, Okajima, M, Saji, S, Sakamoto, J & Tomita, N 2017, 'Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9)', International Journal of Clinical Oncology, vol. 22, no. 4, pp. 805-806. https://doi.org/10.1007/s10147-017-1146-6

Erratum to : Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9). / Suto, Takeshi; Ishiguro, Megumi; Hamada, Chikuma; Kunieda, Katsuyuki; Masuko, Hiroyuki; Kondo, Ken; Ishida, Hideyuki; Nishimura, Genichi; Sasaki, Kazuaki; Morita, Takayuki; Hazama, Shoichi; Maeda, Koutarou; Mishima, Hideyuki; Ike, Hideyuki; Sadahiro, Sotaro; Sugihara, Kenichi; Okajima, Masazumi; Saji, Shigetoyo; Sakamoto, Junichi; Tomita, Naohiro.

In: International Journal of Clinical Oncology, Vol. 22, No. 4, 01.08.2017, p. 805-806.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Erratum to

T2 - Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9)

AU - Suto, Takeshi

AU - Ishiguro, Megumi

AU - Hamada, Chikuma

AU - Kunieda, Katsuyuki

AU - Masuko, Hiroyuki

AU - Kondo, Ken

AU - Ishida, Hideyuki

AU - Nishimura, Genichi

AU - Sasaki, Kazuaki

AU - Morita, Takayuki

AU - Hazama, Shoichi

AU - Maeda, Koutarou

AU - Mishima, Hideyuki

AU - Ike, Hideyuki

AU - Sadahiro, Sotaro

AU - Sugihara, Kenichi

AU - Okajima, Masazumi

AU - Saji, Shigetoyo

AU - Sakamoto, Junichi

AU - Tomita, Naohiro

PY - 2017/8/1

Y1 - 2017/8/1

N2 - In the original publication of the article, Fig. 1 was published with incorrect numbers of patients (n). The correct Fig. 1 is given in this erratum.

AB - In the original publication of the article, Fig. 1 was published with incorrect numbers of patients (n). The correct Fig. 1 is given in this erratum.

UR - http://www.scopus.com/inward/record.url?scp=85020734681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020734681&partnerID=8YFLogxK

U2 - 10.1007/s10147-017-1146-6

DO - 10.1007/s10147-017-1146-6

M3 - Comment/debate

C2 - 28608229

AN - SCOPUS:85020734681

VL - 22

SP - 805

EP - 806

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 4

ER -

Suto T, Ishiguro M, Hamada C, Kunieda K, Masuko H, Kondo K et al. Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9). International Journal of Clinical Oncology. 2017 Aug 1;22(4):805-806. https://doi.org/10.1007/s10147-017-1146-6

Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9)

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this